Daniel S. Chen

45.9k total citations · 9 hit papers
50 papers, 20.1k citations indexed

About

Daniel S. Chen is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Daniel S. Chen has authored 50 papers receiving a total of 20.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 22 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Daniel S. Chen's work include Cancer Immunotherapy and Biomarkers (31 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (14 papers). Daniel S. Chen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (31 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (14 papers). Daniel S. Chen collaborates with scholars based in United States, France and United Kingdom. Daniel S. Chen's co-authors include Ira Mellman, Priti S. Hegde, Napoleone Ferrara, Rajendra S. Apte, Thomas Powles, F. Stephen Hodi, Bryan Irving, Gregg Fine, Marcin Kowanetz and Marcus Ballinger and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Daniel S. Chen

49 papers receiving 19.7k citations

Hit Papers

Oncology Meets Immunology: The Cancer-Immunity Cycle 2012 2026 2016 2021 2013 2017 2016 2019 2014 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oncology Meets Immunology: The Cancer-Immunity Cycle
    2013 4.9k citations Daniel S. Chen, Ira Mellman Immunity profile →
  2. Elements of cancer immunity and the cancer–immune set point
    2017 3.6k citations Daniel S. Chen, Ira Mellman Nature profile →
  3. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    2016 2.1k citations Louis Fehrenbacher, Alexander I. Spira et al. profile →
  4. VEGF in Signaling and Disease: Beyond Discovery and Development
    2019 1.9k citations Daniel S. Chen et al. profile →
  5. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    2014 1.9k citations Thomas Powles, Joseph P. Eder et al. Nature profile →
  6. Top 10 Challenges in Cancer Immunotherapy
    2020 1.4k citations Priti S. Hegde, Daniel S. Chen Immunity profile →
  7. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    2012 496 citations Daniel S. Chen, Bryan Irving et al. Clinical Cancer Research profile →
  8. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    2016 490 citations Daniel S. Chen et al. profile →
  9. The cancer-immunity cycle: Indication, genotype, and immunotype
    2023 444 citations Ira Mellman, Daniel S. Chen et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel S. Chen United States 29 13.3k 8.5k 5.1k 4.6k 2.6k 50 20.1k
Mario Sznol United States 67 13.8k 1.0× 7.8k 0.9× 5.6k 1.1× 4.3k 0.9× 1.6k 0.6× 270 19.8k
Sandra Demaria United States 65 14.7k 1.1× 10.6k 1.2× 3.6k 0.7× 4.8k 1.0× 2.3k 0.9× 192 21.7k
Robert H. Vonderheide United States 74 15.2k 1.1× 14.2k 1.7× 6.9k 1.4× 2.4k 0.5× 3.2k 1.2× 224 25.0k
Padmanee Sharma United States 63 20.0k 1.5× 13.9k 1.6× 6.5k 1.3× 5.8k 1.3× 2.9k 1.1× 257 28.5k
Janis M. Taube United States 55 15.5k 1.2× 7.9k 0.9× 3.6k 0.7× 4.8k 1.0× 2.3k 0.9× 205 20.7k
Richard M. Sherry United States 51 18.5k 1.4× 13.8k 1.6× 6.1k 1.2× 2.8k 0.6× 1.7k 0.7× 97 25.0k
Jennifer A. Wargo United States 68 15.9k 1.2× 8.2k 1.0× 11.4k 2.2× 3.6k 0.8× 2.9k 1.1× 263 25.5k
José Luis Perez‐Gracia Spain 51 10.4k 0.8× 5.7k 0.7× 2.8k 0.6× 5.0k 1.1× 1.9k 0.7× 191 15.2k
Aurélien Marabelle France 63 10.2k 0.8× 5.8k 0.7× 2.8k 0.5× 3.1k 0.7× 1.6k 0.6× 281 15.2k
Ignacio Melero Spain 88 15.8k 1.2× 16.8k 2.0× 6.6k 1.3× 3.0k 0.7× 2.4k 0.9× 396 28.2k

Countries citing papers authored by Daniel S. Chen

Since Specialization
Citations

This map shows the geographic impact of Daniel S. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Chen more than expected).

Fields of papers citing papers by Daniel S. Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel S. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Chen. The network helps show where Daniel S. Chen may publish in the future.

Co-authorship network of co-authors of Daniel S. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel S. Chen. A scholar is included among the top collaborators of Daniel S. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel S. Chen. Daniel S. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atkins, Michael B., Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.. (2022). Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for ImmunoTherapy of Cancer. 10(9). e005413–e005413. 7 indexed citations
2.
Baliga, Ramesh, Keyu Li, Paul R. Hinton, et al.. (2020). Abstract 5664: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release. Cancer Research. 80(16_Supplement). 5664–5664. 3 indexed citations
3.
Hamid, Omid, Luciana Molinero, Christopher R. Bolen, et al.. (2019). Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research. 25(20). 6061–6072. 58 indexed citations
4.
Chen, Daniel S. & Herbert I. Hurwitz. (2018). Combinations of Bevacizumab With Cancer Immunotherapy. The Cancer Journal. 24(4). 193–204. 152 indexed citations
5.
Hodi, F. Stephen, Marcus Ballinger, Benjamin Lyons, et al.. (2018). Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology. 36(9). 850–858. 242 indexed citations
6.
Chen, Daniel S. & Ira Mellman. (2017). Elements of cancer immunity and the cancer–immune set point. Nature. 541(7637). 321–330. 3575 indexed citations breakdown →
7.
Smith, David A., Johan Vansteenkiste, Louis Fehrenbacher, et al.. (2016). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology. 34(15_suppl). 9028–9028. 22 indexed citations
8.
Powles, Thomas, Joseph P. Eder, Gregg Fine, et al.. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515(7528). 558–562. 1850 indexed citations breakdown →
9.
Chang, Chiung‐Hung, Bi Yu, Daniel S. Chen, et al.. (2014). Coptidis rhizome and Si Jun Zi Tang Can Prevent Salmonella enterica Serovar Typhimurium Infection in Mice. PLoS ONE. 9(8). e105362–e105362. 21 indexed citations
10.
Chen, Daniel S. & Ira Mellman. (2013). Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 39(1). 1–10. 4864 indexed citations breakdown →
11.
Gordon, Michael S., Omid Hamid, John D. Powderly, et al.. (2013). Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Cancer Research. 73(8_Supplement). LB–288. 11 indexed citations
12.
Hegde, Priti S., Adrian M. Jubb, Yong Meng, et al.. (2012). Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab. Clinical Cancer Research. 19(4). 929–937. 152 indexed citations
13.
14.
Chen, Daniel S., Bryan Irving, & F. Stephen Hodi. (2012). Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clinical Cancer Research. 18(24). 6580–6587. 496 indexed citations breakdown →
15.
Jubb, Adrian M., Kathy D. Miller, Hope S. Rugo, et al.. (2011). Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research. 17(2). 372–381. 79 indexed citations
16.
Kim, Kevin B., Jeffrey A. Sosman, John P. Fruehauf, et al.. (2011). BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology. 30(1). 34–41. 148 indexed citations
17.
Huse, Morgan, Björn F. Lillemeier, Michael S. Kuhns, Daniel S. Chen, & Mark M. Davis. (2006). T cells use two directionally distinct pathways for cytokine secretion. Nature Immunology. 7(3). 247–255. 344 indexed citations
18.
Chen, Daniel S. & Mark M. Davis. (2005). Cellular immunotherapy: antigen recognition is just the beginning. Springer Seminars in Immunopathology. 27(1). 119–127. 10 indexed citations
19.
Chen, Daniel S., Nian‐Ling Zhu, Gene Hung, et al.. (1997). Retroviral Vector-Mediated Transfer of an Antisense Cyclin G1 Construct Inhibits Osteosarcoma Tumor Growth in Nude Mice. Human Gene Therapy. 8(14). 1667–1674. 39 indexed citations
20.
Chen, Daniel S., et al.. (1997). Human carcinoembryonic antigen and biliary glycoprotein can serve as mouse hepatitis virus receptors. Journal of Virology. 71(2). 1688–1691. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Sandra Demaria Breakdown of academic impact, for papers by Robert H. Vonderheide Breakdown of academic impact, for papers by Padmanee Sharma Breakdown of academic impact, for papers by Janis M. Taube Breakdown of academic impact, for papers by Richard M. Sherry Breakdown of academic impact, for papers by Jennifer A. Wargo Breakdown of academic impact, for papers by José Luis Perez‐Gracia Breakdown of academic impact, for papers by Aurélien Marabelle Breakdown of academic impact, for papers by Ignacio Melero
Rankless by CCL
2026